JP2005533036A5 - - Google Patents

Download PDF

Info

Publication number
JP2005533036A5
JP2005533036A5 JP2004508891A JP2004508891A JP2005533036A5 JP 2005533036 A5 JP2005533036 A5 JP 2005533036A5 JP 2004508891 A JP2004508891 A JP 2004508891A JP 2004508891 A JP2004508891 A JP 2004508891A JP 2005533036 A5 JP2005533036 A5 JP 2005533036A5
Authority
JP
Japan
Prior art keywords
ester
long
solution according
acting
progestogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004508891A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005533036A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2003/050192 external-priority patent/WO2003101539A1/en
Publication of JP2005533036A publication Critical patent/JP2005533036A/ja
Publication of JP2005533036A5 publication Critical patent/JP2005533036A5/ja
Pending legal-status Critical Current

Links

JP2004508891A 2002-05-30 2003-05-23 油性溶液の自己投与型避妊注射 Pending JP2005533036A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02077126 2002-05-30
PCT/EP2003/050192 WO2003101539A1 (en) 2002-05-30 2003-05-23 Self-administered contraceptive injection of oily solution

Publications (2)

Publication Number Publication Date
JP2005533036A JP2005533036A (ja) 2005-11-04
JP2005533036A5 true JP2005533036A5 (https=) 2006-07-06

Family

ID=29595016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004508891A Pending JP2005533036A (ja) 2002-05-30 2003-05-23 油性溶液の自己投与型避妊注射

Country Status (23)

Country Link
US (1) US20060094698A1 (https=)
EP (1) EP1513587A1 (https=)
JP (1) JP2005533036A (https=)
KR (1) KR20050010014A (https=)
CN (1) CN1298330C (https=)
AR (1) AR040131A1 (https=)
AU (1) AU2003238084A1 (https=)
BR (1) BR0311423A (https=)
CA (1) CA2487639A1 (https=)
HR (1) HRP20041126A2 (https=)
IL (1) IL165204A0 (https=)
IS (1) IS7539A (https=)
MX (1) MXPA04011928A (https=)
NO (1) NO20044976L (https=)
NZ (1) NZ536735A (https=)
PE (1) PE20040676A1 (https=)
PL (1) PL373074A1 (https=)
RS (1) RS100904A (https=)
RU (1) RU2328289C2 (https=)
TW (1) TW200404552A (https=)
UA (1) UA80822C2 (https=)
WO (1) WO2003101539A1 (https=)
ZA (1) ZA200409646B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200727920A (en) * 2005-06-21 2007-08-01 Organon Nv New regimens for oral monophasic contraceptives
JP6457383B2 (ja) * 2012-04-06 2019-01-23 アンタレス・ファーマ・インコーポレーテッド テストステロン組成物の針支援式ジェット注入投与
WO2014093818A2 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
EP4349383A3 (en) * 2013-02-11 2024-06-19 Antares Pharma, Inc. Needle assisted jet injection device having reduced trigger force
US10369340B2 (en) 2013-08-12 2019-08-06 Nanomedical Systems, Inc. Device and method for sustained release of low water solubility therapeutic agent in solubilizer
US10792292B2 (en) * 2019-03-06 2020-10-06 Propella Therapeutics, Inc. Abiraterone prodrugs
CN111057120B (zh) * 2019-12-27 2021-04-27 苏州翔实医药发展有限公司 一种依托孕烯衍生物a及其制备方法和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2970153A (en) * 1959-07-27 1961-01-31 Leo Ab Alkoxyphenyl-propionyl esters of 17alpha-hydroxyprogesterone
DE3836862A1 (de) * 1988-10-27 1990-05-03 Schering Ag Mittel zur transdermalen applikation von steroidhormonen
CN1102095A (zh) * 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
CZ187796A3 (en) * 1993-12-27 1997-01-15 Akzo Nobel Nv Pharmaceutical preparation
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
AU6614096A (en) * 1995-07-17 1997-02-18 Schering Aktiengesellschaft Agent, for transdermal application, containing esters of 3-ketodesogestrel
DE69901250T2 (de) * 1998-06-19 2002-10-17 Akzo Nobel N.V., Arnheim/Arnhem 7.alpha.-methyl 19-nortestosteron undecanoat mit androgenischer aktivität
WO1999067270A1 (en) * 1998-06-19 1999-12-29 Akzo Nobel N.V. Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
ATE474580T1 (de) * 2000-02-15 2010-08-15 Bayer Schering Pharma Ag Zusammensetzung zur männlichen kontrazeption, norethisteron enthaltend
EP1313511B1 (en) * 2000-08-23 2005-11-30 Akzo Nobel N.V. Testosterone ester formulation for human use

Similar Documents

Publication Publication Date Title
EP1743646A3 (en) Methods and pharmaceutical compositions for reliable achievement of acceptable serum testosterone levels
JP2022180619A (ja) 薬物粒子を含有する医薬懸濁液、それらの投与のためのデバイス、およびそれらの使用方法
ES2253423T3 (es) Formulacion de un ester de testosterona para uso humano.
JP2003519659A5 (https=)
WO2008093772A1 (ja) 経皮または経粘膜投与のためのアジュバントおよびこれを含む医薬製剤
BR0107445A (pt) Formulação farmacêutica, uso de fulvestrante na preparação de uma formulação farmacêutica, e, seringa ou frasco
RU2009120528A (ru) Способы гормональной терапии возрастающими дозами в режиме пролонгированного цикла
JP2005533036A5 (https=)
AU2001291775A1 (en) Testosterone ester formulation for human use
JP2003512474A5 (https=)
EA200100108A1 (ru) Применение биогенных сульфаматов эстрогенов для гормонзаместительной терапии
WO2020188448A1 (en) Toll-like receptor agonists for use in the treatment of hepatitis b
RU2004138811A (ru) Контрацептивная инъекция масляного раствора, вводимая самостоятельно
BR112012015016B8 (pt) formulação farmacêutica, forma de dosagem farmacêutica entérica e uso de uma formulação
KR960014152A (ko) 17-스피로메틸렌 락톤 또는 락톨 그룹을 갖는 스테로이드
US4181721A (en) Depot preparations in an oily, unsaturated solution for intramuscular injection
Waizmann et al. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD)(PEGASYS) and once-daily ribavirin
JP2005532336A5 (https=)
JP2003522795A5 (https=)
AP1707A (en) Contraceptive medicament based on a progesterone and an oestrogen and method for producing the same.
CN1597005A (zh) 自废式一次性无菌注射器
CN2907715Y (zh) 一次性注射装置
CN2511317Y (zh) 防回拉一次性注射器
CN200966822Y (zh) 安全注射装置
CN202777309U (zh) 用于肌肉注射的注射器